Floatz logo

Pasireotide

Surgery

Zealand University Hospitalprotein_peptidePhase 4 / ApprovedDormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
46/ 100
Competitive Position
81/ 100

Competitive context

46 Active assets in the Surgery cohort.

Asset / SponsorPhaseRating
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
Ain Shams University
Phase 4BB
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE
University of California, Davis
Phase 4BB
ROPIVACAINE
Claus Anders Bertelsen, PhD, MD
Phase 4BB
Ferric Carboxymaltose [Ferinject]
Jon Unosson
Phase 4BB
PROPOFOL
Samsung Medical Center
Phase 4BB

View all 50 →

Same molecule, other indications

Pasireotide is also rated in:

prostate cancerDormant
BB
Indicative ·
69 / 100
View asset →
neuroendocrine neoplasmDormant
BB
Indicative ·
65 / 100
View asset →
dumping syndromeDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →